ARIAA: saw 18m results #EULAR2022 (alluded to at #ACR21) High-risk ACPA+ clinically suspect arthralgias Didn't progress to arthritis: after 6m abatacept: 92% vs 65% 12m after abatacept stopped: 65% vs 43% (tighter at points) How to pick those that benefit? POS0531 @RheumNow https://t.co/dkf1jU5gx7